MedTrace Logo

PK Effects of SHR4640 on Repaglinide and Midazolam, and the Impact of SHR4640 on QT Interval

NCT06196580 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2024-03-06

No results posted yet for this study

Summary

The purpose of this study is to evaluate the PK effects of SHR4640 tablets on repaglinide and midazolam, as well as the effects of SHR4640 tablets on the QT interval in healthy subjects.

Conditions

  • Gout and Hyperuricemia

Interventions

DRUG

repaglinide; midazolam; SHR4640

repaglinide; midazolam; SHR4640

DRUG

repaglinide; midazolam; SHR4640; SHR4640 placebo

repaglinide; midazolam; SHR4640; SHR4640 placebo

DRUG

repaglinide; midazolam; SHR4640 placebo

repaglinide; midazolam; SHR4640 placebo

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-01-04
Primary Completion
2024-02-16
Completion
2024-02-16

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06196580 on ClinicalTrials.gov